EyePoint Inc Dossier - Source-backed chat

EyePoint Inc

EYPTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.48

Intrinsic Value $4.96median of 2 methodsbased on filings through 30 Jun 2026

Market Price $3.23Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 53% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+53%)

Data confidence Sign in to view data confidence

Market Cap $270.8M

Enterprise Value $160.3M

Shares Outstanding 89.7M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

EyePoint Pharmaceuticals is a high-conviction clinical-stage biopharmaceutical company poised for significant near-term catalysts. The investment thesis centers on its lead product candidate, DURAVYU (EYP-1901), a sustained-release tyrosine kinase inhibitor (vorolanib) utilizing the bioerodible Durasert E technology. DURAVYU addresses a massive unmet need in retinal diseases (wet AMD and DME) by potentially reducing the treatment burden from monthly/bimonthly injections to a 6-month dosing interval. With Phase 3 wet AMD trials (LUGANO and LUCIA) fully enrolled and topline data readouts starting in mid-2026, EyePoint is well-positioned to be first-to-file and first-to-market among current investigational sustained-delivery programs. Backed by a robust cash runway extending into Q4 2027, the company is fully funded through these critical clinical milestones.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$36.62

High · most bullish analyst$68.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Phase 3 wet AMD trials fail to meet the non-inferiority primary endpoint or reveal unexpected safety signals (e.g., intraocular inflammation), severely damaging DURAVYU's commercial viability. Delays in DME enrollment or clinical setbacks exhaust the cash runway earlier than expected, forcing highly dilutive equity financing.

Base CaseCentral scenario

The Phase 3 LUGANO and LUCIA trials demonstrate statistical non-inferiority in Best-Corrected Visual Acuity (BCVA) compared to aflibercept, with a favorable safety profile and a significant reduction in treatment burden. EyePoint successfully files its NDA for wet AMD in 2027, paving the way for commercial launch. DME trials (COMO and CAPRI) complete enrollment on schedule in Q3 2026, keeping the H2 2027 data readout on track.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

DURAVYU's highly differentiated 6-month sustained-release profile significantly reduces patient and physician treatment burden.
Phase 3 wet AMD trials are fully enrolled with topline data readouts starting in mid-2026, representing a near-term high-impact catalyst.
Strong balance sheet with $223 million in cash and investments as of March 31, 2026, providing a runway into Q4 2027.
Established regulatory pathway using a non-inferiority design against an on-label aflibercept control.

Key Investment Risks

Clinical trial risk: Failure to meet the non-inferiority primary endpoint in BCVA for wet AMD.
Safety risk: Potential for rare but severe ocular adverse events such as endophthalmitis or vasculitis.
Commercial execution and competition from established blockbusters (e.g., Eylea, Vabysmo) and other long-acting platforms in development.

Thesis Invalidation Triggers

Failure of the LUGANO or LUCIA Phase 3 trials to meet their primary non-inferiority endpoints.
Emergence of serious drug-related ocular safety signals during Phase 3 trials.
Significant delays in the enrollment or execution of the COMO and CAPRI Phase 3 trials for DME.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.